Protagonist Therapeutics: Q1 Earnings Snapshot
ICOTYDE™ (icotrokinra) approved by FDA in March for moderate-to-severe plaque psoriasis, triggering a $50 million milestone payment; Protagonist receives tiered royalties of 6% to 10% and is eligible...
Barchart Research What to Expect from PTGX Earnings PTGX Generated May 4, 2026 Current Price $99.52 EPS Estimate $$-0.65 Consensus Rating Strong Buy Average Move 3.25% PTGX: The Partnership Everyone's...
Opt-out election makes Protagonist eligible for $200 million upon exercise and an additional $200 million upon FDA approval of rusfertide for polycythemia vera
NEWARK, CA / ACCESS Newswire / April 16, 2026 / Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today reported that on April 15, 2026, it issued inducement awards to two recently hired employees in accordance...
One-year Phase 3 data for ICOTYDE to be presented at AAD 2026 demonstrate lasting skin clearance and a favorable safety profile in a once daily pill for moderate-to-severe plaque psoriasis
ICOTYDE is the first and only IL-23R targeted oral peptide that delivers complete skin clearance and a favorable safety profile in a once-daily pill
Rusfertide Demonstrated Significant Improvements in Hematocrit Control, Phlebotomy Reduction and Patient Reported Outcomes for Patients with Polycythemia Vera in a Pivotal Study ...
Protagonist Therapeutics: Q4 Earnings Snapshot
(This release updates the release that posted earlier on February 25, 2026 to update the sub headlines.)